Oral-B SmartSeries toothbrush with Bluetooth connectivity now on sale
CINCINNATI — After making headlines with its debut at Mobile World Congress in February, the Oral-B interactive SmartSeries electric toothbrush with Bluetooth 4.0 connectivity is now on sale, Procter & Gamble has announced.
The Oral-B SmartSeries with Bluetooth 4.0 connectivity is on sale in the United Kingdom after initial, limited quantities sold out.
The SmartSeries 6000 with Bluetooth connectivity now is available at retailers including boots.com and Amazon.co.uk in the United Kingdom at the recommended retail price of £229.
Wider Western Europe and North American sales will begin in fall, with remaining regions throughout the world scheduled for 2015.
The Oral-B App is available free on iOS in the United Kingdom and United States, and will be available for Android devices in August. It will be available in Western Europe, Asia, Australia and New Zealand through July, August and September and in remaining regions in 2015.
The Oral-B SmartSeries works with the Oral-B App to set a new standard in personal oral care for the connected consumer interested in monitoring, guiding and creating smarter, more personalized brushing routines to develop better habits to drive improved outcomes of dental appointments.
“Oral-B has a long history of innovation in oral care, and this is one of the most widely anticipated products in our more than 60 year history. The worldwide reception from consumers, dental professionals and retail customers has been incredible,” said Wayne Randall, VP, global oral care at Procter and Gamble. “The possibilities for improved oral health offered by data-based solutions and increased collaboration between patients and dental professionals are significant and exciting trends, and we’re proud to be the pioneer in the space.”
Prices will vary and all pricing, merchandising, shelving, and distribution decisions are at the sole discretion of the retailer.
Report: FTC stepping up probes of pay-for-delay settlements
NEW YORK — The Federal Trade Commission is stepping up probes of pay-for-delay settlements — pharmaceutical deals that delay the sale of generic drugs — according to a report published Monday by Bloomberg.
According to the report, the FTC has opened new investigations into agreements between generic and brand-name drugmakers. “Our goal is to bring an end to this practice by whatever means are available to us,” Markus Meier, head of the agency’s healthcare division, told Bloomberg.
The enforcement efforts gained credence last year when the Supreme Court ruled antitrust law may bar deals in which brand-name drugmakers compensate generics producers for delaying sales of a particular medication, the report noted.
Kevin Holt to lead Delhaize Group’s U.S. operations as CEO
BRUSSELS, Belgium — Delhaize Group has appointed former Supervalu executive Kevin Holt as CEO for Delhaize America, effective July 7.
Holt, who previously served as president of retail operations at Supervalu, also will become a member of the Delhaize Group executive committee.
“I am very pleased to have Kevin join our team,” said Frans Muller, president and CEO of Delhaize Group. “Kevin brings both deep industry experience [and] a comprehensive customer orientation that will help our U.S. operations to continue to implement our existing strategy and build on the strong momentum of recent quarters. I am looking forward to working with him.”
Holt comes to Delhaize Group with more than 20 years of retail leadership experience in operations, strategy and information technology. Prior to Supervalu, he served for three years with Sears Holding Co. and 14 years with Meijer, working in various leadership positions including EVP of retail operations and SVP of information technology/services and strategic planning.